Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fresenius Kabi Oncology

- PMLiVE

Eli Lilly shares positive late-stage results for Retevmo in thyroid cancer

Medullary thyroid cancer only accounts for up to 2% of thyroid cancers in the US

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by EC for expanded melanoma use

The global incidence of skin cancer has been rising steadily over the past few decades

- PMLiVE

Janssen’s Tecvayli approved by EC for reduced dosing frequency in multiple myeloma

Tecvayli was the first BCMA-targeting bispecific antibody to be approved in Europe

- PMLiVE

Merck shares positive late-stage results for Welireg in advanced kidney cancer

Renal cell carcinoma accounts for approximately 90% of kidney cancer diagnoses

- PMLiVE

NHS expands diagnostic capabilities to reform cancer standards for patients

Thousands of patients are set to receive faster diagnosis and treatment

- PMLiVE

US study finds potential new way of improving immunotherapy for tumours

‘Warming up’ cold tumours assisted immunotherapy in tackling tumours

- PMLiVE

NICE recommends AI technologies for radiotherapy treatment planning

AI technology could provide the NHS with significant time and cost benefits

- PMLiVE

US survey reveals ‘critical’ drug shortages are affecting cancer care

Approximately 99% of US pharmacists reported that they are experiencing drug shortages

- PMLiVE

Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer

The therapy showed an overall response rate of more than 70% in a broad range of patients

- PMLiVE

Novo Nordisk to acquire metabolic disorders specialist Inversago Pharma for $1bn

The deal includes a CB1 blocker being developed to treat metabolic syndrome and its associated complications

- PMLiVE

Gilead and Arcus drop A2R inhibitor in prostate cancer following early data analysis

The candidate is also being evaluated in second- and third-line metastatic colorectal cancer

- PMLiVE

BioNTech and Duality Biologics add third ADC candidate to oncology partnership

The companies announced the original agreement covering two antibody-drug conjugates in April

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links